RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

If you find yourself jolting awake in the early morning hours, it may not necessarily be due to unexplained insomnia. Instead ...

An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Glucagon-like peptide 1 receptor agonists ... A large population-based analysis in Diabetes, Obesity and Metabolism assessed whether certain genetic variants might help explain these effects.

The liver and pancreas are the main actors in glucose metabolism, but not the only ones. Muscles, adipose tissue and the brain play different roles. However, the prize for the best new actor in ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

Glucagon-like peptide 1 receptor agonists ... A large population-based analysis in Diabetes, Obesity and Metabolism assessed whether certain genetic variants might help explain these effects.